This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Blind Clinical Trial

FARRINGTON DANIELS, Jr., M.D.; CARL E. HOPKINS, Ph.D.; THOMAS B. FITZPATRICK, M.D., Ph.D.

AMA Arch Derm. 1958;77(5):503-507.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

Following the introduction of methoxsalen (8-methoxypsoralen, Oxsoralen, Xanthotoxin) into this country for the treatment of vitiligo,¹ there was observed an increased melanin (pigmentation) and tolerance to sunlight in the nondiseased areas of some vitiligo patients taking this drug plus sunlight. This led to preliminary trials of the preparation in subjects with tendency to sunburn and poor tanning. Enthusiastic testimonial evidence was rapidly obtained from users of the material who claimed reduced sunburn and increased tanning. Laboratory and field trials² indicated that pigmentation responses to sun could be augmented in human subjects with either topical or oral use of this compound. As previously reported, a sunburn or sunburn-like reaction could also be produced.²

That tolerance to sun and capacity to develop a "healthy-looking" tan are associated with various value systems in our culture is confirmed by the many letters received from patients pleading . . . [Full Text PDF of this Article]

Author Affiliations
M.P.H.; M.P.H.; Portland, Ore.

Footnotes
Submitted for publication Dec. 5, 1957.

University of Oregon Medical School.

Supported in part by grant No. C-2837 PET, of the National Institutes of Health.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?